Table 2

Characteristics of participants

Number of participants20496
 19959959 (48.6%)
 199610537 (51.4%)
Age (years)
 30–395340 (26.1%)
 40–494822 (23.5%)
 50–593821 (18.6%)
 60–693371 (16.5%)
 70–792365 (11.5%)
 ≥80777 (3.8%)
Sex
 Male9643 (47.1%)
 Female10853 (53.0%)
Smoking status
 Current5191 (25.3%)
 Ex-regular6187 (30.2%)
 Never regular9115 (44.5%)
Reported respiratory conditions
 Reported asthma diagnosis2180 (10.6%)
  First wheezed before age 30 years1289 (6.3%)
 Reported diagnosis of chronic bronchitis or emphysema291 (1.4%)
 Other respiratory condition*489 (2.4%)
Reported respiratory symptoms
 Dyspnoea5425 (26.5%)
  MRC grade 3 or worse2223 (10.9%)
 Wheeze4422 (21.6%)
 Chronic cough2783 (13.6%)
 Chronic phlegm2181 (10.6%)
 Frequent winter bronchitis3447 (16.8%)
 Any of the above respiratory symptoms8410 (41.0%)
Airways obstruction
 GOLD2872 (14.0%)
 NICE1305 (6.4%)
 Single LLN1796 (8.8%)
 Double LLN733 (3.6%)
Clinically significant COPD Reporting diagnosis of chronic bronchitis/emphysema
 GOLD+symptoms91628 (7.9%)145 (8.9%)
 NICE+symptoms971 (4.7%)131 (13.5%)
 Single LLN+symptoms1072 (5.2%)113 (10.5%)
 Double LLN+symptoms571 (2.8%)99 (17.3%)
  • * Excluding hayfever.

  • Prebronchodilator values with childhood asthmatics reclassified (see the Methods section).

  • Respiratory symptoms and airflow obstruction.

  • GOLD=FEV1/FVC <0.7; NICE=FEV1/FVC <0.7 and FEV1 <80% predicted; single LLN=FEV1/FVC <5th percentile of healthy never-smoking population; double LLN=FEV1/FVC <5th percentile and FEV1 <5th percentile.

  • COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; LLN, lower limit of normal; MRC, Medical Research Council; NICE, National Institute for Health and Clinical Excellence.